Prospective observational cohort study on the correlation of microbiome diversity and oncological outcome in immune checkpoint inhibitor therapy - MicrobiomCheckpoint01

Rheinische Friedrich-Wilhelms-Universität Bonn0 个研究点目标入组 100 人开始时间: 2022年11月11日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Voluntarily agree to participate in this study, fully understand the study and sign the informed consent form (ICF).
•=18 years old
•Are you planning treatment with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, or anti-CTLA-4) alone or in combination with another checkpoint inhibitor or treatment agent or modality (eg, B. Targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with the use of the active substance approved by the EMA/BfArM
•Life expectancy = 6 months
•Willingness to provide stool samples for research purposes

•Voluntarily agree to participate in this study, fully understand the study and sign the informed consent form (ICF).
•=18 years old
•Are you planning treatment with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, or anti-CTLA-4) alone or in combination with another checkpoint inhibitor or treatment agent or modality (eg, B. Targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with the use of the active substance approved by the EMA/BfArM
•Life expectancy = 6 months
•Willingness to provide stool samples for research purposes

发起方